对奥马利祖马布用于耐火性克隆性和非克隆性巨细胞激活综合征的系统审查
Meghan V Matheny1, Timothy Craig1, Taha Al-Shaikhly1
1From the Section of Allergy, Asthma and Immunology, Medicine and Pediatrics, Pennsylvania State University School of Medicine, Hershey, Pennsylvania and.
Allergy and asthma proceedings
|December 31, 2024
概括
奥马利祖马布为患有对标准疗法的耐药性巨细胞激活综合征 (MCAS) 患者提供了一个有前途的治疗方法. 本综述显示,在大多数耐火性MCAS病例中,奥马利祖马布显著减少了症状.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 乳腺细胞激活综合征 (MCAS) 患者往往对传统的抗中介治疗有抗性.
- 迫切需要替代疗法来减轻MCAS疾病负担并提高患者的生活质量.
研究的目的:
- 系统地审查和分析现有证据支持奥马利祖马布作为耐火性巨细胞激活综合征 (MCAS) 的治疗方法.
主要方法:
- 对PubMed数据库进行了系统审查.
- 从9项涉及28名耐火性MCAS患者的研究中收集和分析了与奥马利祖马布治疗的数据.
- 临床反应被分为没有,部分或完全.
主要成果:
- 奥马利祖马布治疗导致大多数耐火性MCAS患者的症状减轻.
- 大多数患者经历了部分反应 (61%),其中5人实现了完全反应.
- 奥马利祖马布有助于控制过敏反应,并使一些患者能够停止服用葡萄糖皮质激素,但没有报告重大不良事件.
结论:
- 在耐火性MCAS患者中,Omalizumab在减少杆细胞介质相关症状方面表现出有效性.
- 这些发现支持奥马利祖马布作为对不响应标准治疗的MCAS病例的可行的治疗选择.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:38Inflammation
52.5K
Overview
52.5K
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
02:06Allergic Reactions
27.2K
Overview
27.2K